HOME >> BIOLOGY >> NEWS
Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial

CALGARY, AB, --- April 11, 2007 - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that subsequent to the regulatory review period for this submission, it is proceeding with a Phase II trial to evaluate the intravenous administration of REOLYSIN in patients with various sarcomas that have metastasized to the lung. The Principal Investigators are Dr. Glenn S. Kroog of the Montefiore Medical Center/Albert Einstein College of Medicine in the Bronx, New York, Dr. Laurence H. Baker of the University of Michigan Comprehensive Cancer Center in Ann Arbor, and Dr. Monica Mita of the Cancer Therapy and Research Center, Institute for Drug Development in San Antonio, Texas.

"This multi-centre, Phase II trial follows the successful completion of systemic administration trials with REOLYSIN in the U.K. and the U.S.," said Dr. Karl Mettinger, Chief Medical Officer of Oncolytics. "This trial is the second in a series of Phase II trials the Company has planned for this year, and represents yet another step forward in the Company's clinical development strategy for REOLYSIN. We are excited to expand our clinical program to specifically include patients with sarcomas."

The trial (REO 014) is a Phase II, open-label, single agent study whose primary objective is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity of intravenous, multiple dose REOLYSIN in patients with bone and soft tissue sarcomas metastatic to the lung. REOLYSIN will be given intravenously to patients at a dose of 3x1010 TCID50 for five consecutive days. Patients may receive additional five-day cycles of therapy every four weeks for a maximum of eight cycles. Up to 52 patients will be enrolled in the study.


'"/>

Contact: Cathy Ward
cathy.ward@oncolytics.ca
403-251-3807
Oncolytics Biotech Inc.
11-Apr-2007


Page: 1

Related biology news :

1. Oncolytics Biotech Inc., research collaborators demonstrate reovirus/gemcitabine
2. Biotech breakthrough could end biodiesels glycerin glut
3. How the Biotech Revolution Is Changing the Way We Fight Disease
4. Rutgers: GM/GMO/Biotech crop containment strategy
5. Ronald Cape to receive 2007 Biotechnology Heritage Award
6. Biotechnology Study Center honors Joan V. Ruderman, Salvador Moncada and Charles N. Serhan
7. European Federation of Biotechnology and Elsevier announce launch of biotechnology journal
8. Advances in Optics for Biotechnology, Medicine and Surgery
9. Biolex reports potential for more potent, efficacious antibodies in Nature Biotechnology
10. Developing uses for sugar-cane bagasse: Biotechnology applied to the paper industry
11. Biotech cotton provides same yield with fewer pesticides

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/12/2020)... ... August 12, 2020 , ... ... systems that are ideal for public health agencies of all sizes. With a ... and helping at-risk individuals find appropriate health care, Mosio helps public health departments ...
(Date:7/31/2020)... , ... July 30, 2020 , ... ... (SBIR) Phase II contract awarded by the Joint Science & Technology Office—Chemical and ... project is to develop, optimize, and scale-up a highly efficient mammalian cell culture-based ...
(Date:7/10/2020)... CHURCH, Va. (PRWEB) , ... July 08, 2020 ... ... The Latest on Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July ... may need a comparability study, but what is the most effective way to ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... ... R3 Stem Cell International is now offering patients the opportunity to receive four ... may choose which extremities they would like treated. , Several studies have shown just ... R3 International, umbilical cord tissue is obtained from a lab with a long history ...
(Date:7/31/2020)... and SOMERSET, N.J (PRWEB) , ... July 29, ... ... genome editing company, and Catalent, the leading global provider of advanced delivery technologies, ... health products, today announced that they have entered into a strategic partnership whereby ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from Reed ... Manager Regulatory Solutions, in a one hour live webinar on Thursday, August ... in China for drugs and medical devices. Specifically, for medical devices, the NMPA has ...
(Date:7/18/2020)... ... July 17, 2020 , ... ... the life sciences and food industries, is pleased to announce that Charles Galea ... – Business Development. , Charles is an accomplished and results-driven sales executive with ...
Breaking Biology Technology:
Cached News: